Caribou Biosciences, Inc. Operating Income
Caribou Biosciences, Inc. (CRBU) reported Operating Income of -$25.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- Caribou Biosciences, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$25.34M.
- Caribou Biosciences, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$26.28M.
- Caribou Biosciences, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$28.45M.
- Caribou Biosciences, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$29.40M.
- Caribou Biosciences, Inc. operating income (loss) for fiscal 2025 was -$148.34M.
- Caribou Biosciences, Inc. operating income (loss) for fiscal 2024 was -$166.62M.
- Caribou Biosciences, Inc. operating income (loss) for fiscal 2023 was -$116.06M.
- Caribou Biosciences, Inc. operating income (loss) for fiscal 2022 was -$106.40M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$25.34M 10-Q · filed 2026-08-13 | -$51.62M 10-Q · filed 2026-08-13 | -$80.07M derived: sum of 3 quarters · filed 2026-08-13 | -$109.47M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$26.28M 10-Q · filed 2026-05-07 | -$54.73M derived: sum of 2 quarters · filed 2026-05-07 | -$84.13M derived: sum of 3 quarters · filed 2026-05-07 | -$131.71M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$28.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$57.85M derived: sum of 2 quarters · filed 2026-03-05 | -$105.43M derived: sum of 3 quarters · filed 2026-08-13 | -$148.34M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$29.40M 10-Q · filed 2025-11-12 | -$76.98M derived: sum of 2 quarters · filed 2026-08-13 | -$119.89M 10-Q · filed 2025-11-12 | -$158.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$47.58M 10-Q · filed 2026-08-13 | -$90.49M 10-Q · filed 2026-08-13 | -$129.37M derived: sum of 3 quarters · filed 2026-08-13 | -$167.60M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$42.91M 10-Q · filed 2026-05-07 | -$81.79M derived: sum of 2 quarters · filed 2026-05-07 | -$120.03M derived: sum of 3 quarters · filed 2026-05-07 | -$163.53M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$38.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$77.11M derived: sum of 2 quarters · filed 2026-03-05 | -$120.61M derived: sum of 3 quarters · filed 2026-03-05 | -$166.62M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$38.24M 10-Q · filed 2025-11-12 | -$81.74M derived: sum of 2 quarters · filed 2025-11-12 | -$127.74M 10-Q · filed 2025-11-12 | -$165.18M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$43.50M 10-Q · filed 2025-08-12 | -$89.50M 10-Q · filed 2025-08-12 | -$126.94M derived: sum of 3 quarters · filed 2025-08-12 | -$141.58M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$46.00M 10-Q · filed 2025-05-08 | -$83.44M derived: sum of 2 quarters · filed 2025-05-08 | -$98.08M derived: sum of 3 quarters · filed 2025-05-08 | -$130.94M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$37.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$52.08M derived: sum of 2 quarters · filed 2025-03-10 | -$84.94M derived: sum of 3 quarters · filed 2025-03-10 | -$116.06M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$14.63M 10-Q · filed 2024-11-06 | -$47.50M derived: sum of 2 quarters · filed 2024-11-06 | -$78.62M 10-Q · filed 2024-11-06 | -$109.19M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$32.87M 10-Q · filed 2024-08-06 | -$63.98M 10-Q · filed 2024-08-06 | -$94.56M derived: sum of 3 quarters · filed 2024-08-06 | -$121.10M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$31.12M 10-Q · filed 2024-05-07 | -$61.69M derived: sum of 2 quarters · filed 2024-05-07 | -$88.23M derived: sum of 3 quarters · filed 2024-05-07 | -$116.66M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$30.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$57.12M derived: sum of 2 quarters · filed 2024-03-11 | -$85.55M derived: sum of 3 quarters · filed 2024-03-11 | -$106.40M 10-K · filed 2024-03-11 |
| 2022-09-30 | -$26.54M 10-Q · filed 2023-11-07 | -$54.97M derived: sum of 2 quarters · filed 2023-11-07 | -$75.82M 10-Q · filed 2023-11-07 | -$96.23M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$28.43M 10-Q · filed 2023-08-08 | -$49.28M 10-Q · filed 2023-08-08 | -$69.69M derived: sum of 3 quarters · filed 2023-08-08 | -$88.31M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$20.85M 10-Q · filed 2023-05-09 | -$41.26M derived: sum of 2 quarters · filed 2023-05-09 | -$59.87M derived: sum of 3 quarters · filed 2023-05-09 | -$75.84M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$20.41M 10-K · filed 2022-03-21 | -$39.02M derived: sum of 2 quarters · filed 2022-11-08 | -$54.98M derived: sum of 3 quarters · filed 2022-11-08 | -$66.98M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$18.62M 10-Q · filed 2022-11-08 | -$34.58M derived: sum of 2 quarters · filed 2022-11-08 | -$46.57M 10-Q · filed 2022-11-08 | -$62.97M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$15.96M 10-Q · filed 2022-08-09 | -$29.14M 10-Q · filed 2021-09-02 | -$44.35M derived: sum of 3 quarters · filed 2022-08-09 | -$52.58M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$13.18M 10-Q · filed 2022-05-09 | -$28.39M derived: sum of 2 quarters · filed 2022-05-09 | -$36.62M derived: sum of 3 quarters · filed 2022-05-09 | -$38.87M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$15.21M 10-K · filed 2022-03-21 | -$23.44M derived: sum of 2 quarters · filed 2022-03-21 | -$25.70M derived: sum of 3 quarters · filed 2022-03-21 | -$36.12M 10-K · filed 2022-03-21 |
| 2020-09-30 | -$8.23M 10-K · filed 2022-03-21 | -$10.48M derived: sum of 2 quarters · filed 2022-03-21 | -$20.91M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$2.25M 10-K · filed 2022-03-21 | -$12.68M 10-Q · filed 2021-09-02 | ||
| 2020-03-31 | -$10.43M 10-K · filed 2022-03-21 | |||
| 2019-12-31 | -$34.30M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |